Best Recombinant Proteins CDMOs in Asia

← All Recombinant Proteins CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia

CDMOs tracked

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

For Asia-manufactured recombinant proteins programs, Pharmaron Biologics, AGC Biologics, and Samsung Biologics lead CDMO Signal's ranking of recombinant proteins CDMOs with confirmed Asian manufacturing sites. Filtered from the global directory of 14 scored recombinant proteins CDMOs to 3 with Asia-Pacific facility presence. Asian CDMOs cover a range of regulatory jurisdictions — PMDA (Japan), NMPA (China), MFDS (South Korea), CDSCO (India) — each with distinct requirements. For sponsors supplying US and EU markets, cross-jurisdictional regulatory posture (FDA and EMA/MHRA inspection history on Asian facilities) is typically the qualifying signal. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Recombinant protein CDMOs make therapeutic proteins, enzymes, and growth factors using microbial (E. coli, yeast) or mammalian (CHO) expression. Choice of host turns on post-translational modification needs, scale economics, and downstream-purification complexity.

Selecting a recombinant protein CDMO turns on host-system experience, validated bioreactor scale, downstream purification and analytics, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 4 NAI (no action), 1 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (18), United States (5), Germany (3), Italy (2).

Last updated 2026-08-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	PB Pharmaron Biologics San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China	86.9	100.0	3 insp · 0 GMP	Available	0 programs
2	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	80.6	99.9	2 insp · 23 GMP	Available	2 programs
3	SB Samsung Biologics Incheon, South Korea, Rockville, Maryland, USA	61.5	—	—	Available	0 programs
—	BioCina Adelaide, Australia	Profiled	—	—	—	0 programs
—	Altruist Biologics Suzhou, China	Profiled	—	—	Available	0 programs
—	EirGenix Zhubei City, Taiwan	Profiled	—	—	—	0 programs
—	Biological E. Limited (BioE) Hyderabad, India	Profiled	—	—	—	0 programs
—	Kemwell Biopharma Bengaluru, India	Profiled	—	—	—	0 programs
—	Kemwell Biopharma, Bangalore Bengaluru, India	Profiled	—	—	—	0 programs
—	BE Biosol (formerly SGI Pharma / Biological E, Samirpet) Hyderabad, India	Profiled	—	—	—	0 programs
—	AsymBio Shanghai, China	Profiled	—	—	—	0 programs
—	Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.) Hangzhou, China	Profiled	—	—	—	0 programs
—	Chime Biologics Wuhan, China	Profiled	—	—	—	0 programs
—	Canton Biologics Co., Ltd. Foshan (Shunde District), China	Profiled	—	—	—	0 programs
—	Canton Biologics Guangzhou, China	Profiled	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a Recombinant Proteins CDMO

Expression host & scale

Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target.

Purification & analytics

Downstream complexity (multiple chromatography steps, refolding for E. coli) drives cost and timeline. Ask about the orthogonal analytics package — purity, identity, potency.

Regulatory readiness

Clean FDA 483 history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.

Capacity & commercial readiness

For programs heading to BLA, evaluate validated commercial scale and any approved-product track record.

Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)

Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.

Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?

Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.

Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)

Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.

Recombinant Proteins CDMOs — Frequently Asked Questions

Who are the top Recombinant Proteins CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Recombinant Proteins CDMOs include Pharmaron Biologics, AGC Biologics, Samsung Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Recombinant Proteins CDMOs have FDA inspection records?

CDMO Signal tracks 2 Recombinant Proteins CDMOs with FDA inspection records and 23 EMA/MHRA GMP certificates across the group.

What should I look for in a recombinant protein CDMO?

Confirm expression-host experience for your target (microbial vs mammalian), validated bioreactor scale, a strong downstream-purification platform, qualified analytics, and a clean FDA and EMA/MHRA record.

How is a recombinant protein CDMO different from a mAb CDMO?

There's significant overlap — mAbs are recombinant proteins. But mAb CDMOs are typically optimized for CHO-based platform processes, while general recombinant protein CDMOs handle a wider range of hosts and non-mAb formats (enzymes, growth factors, complex non-glycoproteins).

Related modalities

Biologics / mAb CDMOs mRNA / LNP CDMOs Cell Therapy CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome ADC